Welcome to our dedicated page for Regenerex Pharma news (Ticker: RGPX), a resource for investors and traders seeking the latest updates and insights on Regenerex Pharma stock.
Regenerex Pharma, Inc. (OTC: RGPX) is a Nevada-based company focused on advanced wound closure systems for chronic and acute wounds. Its news flow centers on product development, clinical positioning, strategic collaborations, and corporate updates related to its QBx™ technology and expanding wound care portfolio.
Recent press releases highlight Regenerex’s efforts to integrate biomaterials and proprietary formulations into its wound care protocols. The company has announced new product formulations built on its QBx™ platform, designed to support deep tissue regeneration and accelerate healing through modulation of proteases and matrix metalloproteases (MMPs). These announcements often emphasize clinical evaluations, targeted wound types such as diabetic foot ulcers and pressure ulcers, and the company’s stated healing performance under defined protocols.
A significant theme in Regenerex’s news is its collaboration with Holista Colltech Ltd., a producer of high-purity ovine collagen. The company has reported a licensing agreement and a binding supply and development agreement covering ovine collagen and nano-collagen technologies. News items describe how ovine nano-collagen will be combined with QBx™ to create advanced wound care products, with initial commercial focus in the United States and planned expansion to other markets.
Corporate communications also cover management structure, manufacturing plans in Memphis, Tennessee, and regulatory milestones such as changes in fiscal year and filing timelines. Investors and healthcare professionals following RGPX news can expect updates on product lines like Xcellderma™ and Accelerex, clinical and regulatory developments, collaboration progress with Holista, and SEC-reported corporate changes. This page aggregates those releases so readers can track how Regenerex’s wound care strategy and partnerships evolve over time.
Regenerex Pharma (OTC: RGPX), a developer of advanced wound closure systems, has signed a binding supply and development agreement with Holista Colltech Ltd. of Perth, Australia. The agreement grants Regenerex exclusive worldwide rights to use Holista's proprietary ovine collagen technologies in wound care applications.
The agreement includes minimum purchase commitments starting at $50,000 in 2025, scaling to $9 million annually from 2028. Regenerex will conduct FDA clinical studies and regulatory approvals, while both companies will collaborate on new nano-collagen applications in wound care. Manufacturing will be conducted at Holista's facilities in Collie and Malaysia under GMP standards.
Regenerex Pharma (OTC: RGPX) has announced a strategic licensing agreement with Holista Colltech Ltd. to incorporate ovine nano-collagen into its QBx™ wound healing technology. The integration aims to enhance deep tissue regeneration through improved scaffolding facilitation and cell proliferation.
The company will utilize Holista's high-purity ovine collagen, sourced from disease-free Australian sheep, which offers advantages over traditional bovine or porcine collagen sources. The nano-collagen's ultra-small molecular size creates an optimal scaffolding matrix for cellular growth, particularly beneficial for deep tissue regeneration cases.
